MI-EATON
16.11.2021 12:32:13 CET | Business Wire | Press release
Power management company Eaton today announced its Vehicle Group has demonstrated cylinder deactivation (CDA) as an effective technology for meeting future global emissions requirements for diesel-engine powered commercial vehicles. To date, the technology has been evaluated with a close-coupled selective catalytic reduction (SCR) aftertreatment system with and without a 48-volt electric heater.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116005234/en/
“Our CDA technology has proven it can help our customers meet increasingly strict emissions regulations for diesel engines,” said Christopher Mancuso, business unit director, Engine Air Management, Eaton’s Vehicle Group. “This comes at a time when many global manufacturers are determining what technologies they will leverage in next-generation vehicles to reduce harmful emissions.”
New emissions regulations spearheaded by the California Air Resources Board (CARB), U.S. Environmental Protection Agency (EPA) and European Commission (EC) are slated for adoption in coming years. These agencies, in concert with other national and international regulators, seek to significantly reduce greenhouse gas (GHG) emissions and harmful air pollutants produced primarily by heavy-duty trucks, vans and buses.
Rapid catalyst warm-up essential
Eaton partnered with the Southwest Research Institute (SwRI), one of the oldest and largest independent, nonprofit, applied research and development organizations in the U.S., to demonstrate the feasibility of its Vehicle Group’s technology. The findings demonstrate that using CDA and a close-coupled SCR catalyst reduced both nitrous oxide (NOx) and carbon dioxide (CO2 ) emissions with fuel consumption savings of up to 40% at idle.
Previous results utilizing CDA and a close-coupled SCR catalyst demonstrated compliance to forthcoming U.S. regulations for NOx and CO2 emissions for diesel commercial vehicles. Testing with the new low-load cycle (LLC) resulted in a 5% drop in CO2 while dramatically reducing NOx. The assessment was developed by CARB to replicate real-world urban tractor and vocational vehicle operations at low engine loads.
Eaton’s 2021 testing with SwRI showed further advancement, dropping NOx levels by 99.4% on the composite federal test procedure (FTP) and lowering the LLC NOx to well within current guidelines. Notably, using the same aftertreatment system with the addition of a 48-volt electric heater located upstream of the SCR further achieved a reduction in CO2 .
CDA technology can benefit vehicle manufacturers facing tightening emissions standards in Europe as well. The next set of requirements, known as Euro VII for heavy-duty trucks, is targeted for the second part of the decade. In the U.S., CARB is introducing more stringent regulations as soon as 2024, while the EPA has circled 2027 to begin applying stricter emissions limits on new-model heavy-duty vehicles. Collectively, these standards are designed to reduce tailpipe NOx emissions up to 90%, accelerating the need for global engine manufacturers to employ additional emissions-reduction strategies such as electric catalyst heating. This technology is an example of how Eaton is progressing toward achieving its 2030 Sustainability Targets . By 2030, the company aims to reduce emissions from its solutions and throughout its value chain by 15%.
Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005234/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
